Hagiwara Akiyoshi, Kimura Akio, Kato Hiroshi, Mizushima Yasuaki, Matsuoka Tetsuya, Takeda Munekazu, Uejima Toshifumi, Hagiwara Yusuke, Sakamoto Yuichiro, Kudo Daisuke, Sasaki Junichi
Department of Traumatology and Critical Care Medicine, National Defense Medical College, Japan.
J Trauma. 2010 Nov;69(5):1161-8. doi: 10.1097/TA.0b013e3181d27c94.
This study sought to define hemorrhagic shock from blood pressure and heart rate and then to provide a treatment policy based on response to initial fluid therapy.
This was a prospective clinical observational study conducted in eight hospitals. Subjects were consecutive patients with trauma who met any of the field triage conditions proposed by the Committee on Trauma of the American College of Surgeons. Initial fluid therapy was performed in patients with suspected hemorrhagic shock. Patients who required blood transfusion ≥ 4 U within 24 hours or interventions for active bleeding within 24 hours were classified into a "bleeding group" (B). A "nonbleeding group" (non-B) comprised patients who did not require blood transfusion ≥ 4 U or other interventions within 24 hours. Our committee maintained the database of survey items. Four of the hospitals were selected at random to provide training data and that was used in a recursive partitioning analysis to predict the B group. Data on patients in the other four facilities were used for validation.
There were a total of 400 patients studied. The training set consisted of 261 patients, 50 of whom were classified into the B group. A total of 94% patients with hemorrhagic shock suspected clinically, shock index at admission (first SI) ≥ 0.8, and SI at 1 L of fluid resuscitation (second SI) ≥ 1.0 were assigned to the B group. The non-B group (92%) were patients those whose first SI was < 0.8 and base deficits at admission ≥ -1.0. Validation data consisted of 139 patients. The sensitivity, specificity, and accuracy of these data to predict the B group were 71%, 93%, and 89%, respectively.
Patients whose first SI was ≥ 0.8 and second SI ≥ 1.0 would be diagnosed as "nonresponders" by American College of Surgeons. Patients with first SI < 0.8 and base deficits ≥ -1.0 will not be candidates for the B group.
本研究旨在根据血压和心率定义出血性休克,然后根据对初始液体治疗的反应提供治疗策略。
这是一项在八家医院进行的前瞻性临床观察研究。研究对象为符合美国外科医师学会创伤委员会提出的任何现场分诊条件的连续创伤患者。对疑似出血性休克的患者进行初始液体治疗。在24小时内需要输血≥4U或在24小时内进行活动性出血干预的患者被分类为“出血组”(B组)。“非出血组”(非B组)包括在24小时内不需要输血≥4U或其他干预的患者。我们的委员会维护调查项目数据库。随机选择四家医院提供训练数据,并将其用于递归划分分析以预测B组。其他四家机构的患者数据用于验证。
共研究了400例患者。训练集包括261例患者,其中50例被分类为B组。临床上疑似出血性休克、入院时休克指数(首次休克指数)≥0.8且液体复苏1L时休克指数(第二次休克指数)≥1.0的患者中,共有94%被分配到B组。非B组(92%)为首次休克指数<0.8且入院时碱缺失≥-1.0的患者。验证数据包括139例患者。这些数据预测B组的敏感性、特异性和准确性分别为71%、93%和89%。
首次休克指数≥0.8且第二次休克指数≥1.0的患者将被美国外科医师学会诊断为“无反应者”。首次休克指数<0.8且碱缺失≥-1.0的患者不是B组的候选者。